RELATED CONTENT
NEWS
- SymBio shifts bendamustine's multiple myeloma focus to second-line use
- AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- SymBio heading to the market in $37mn Japanese IPO
FEATURES
Other Informa Features
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK

Section Head (m/f)
DRA International/CIS Section

Section Head (m/f)
DRA International/CIS Section

